spacer
home > ebr > Spring 2013
PUBLICATIONS

European Biopharmaceutical Review

ebr
Spring 2013

   
Text
PDF
bullet
BioBusiness Development
Outsourcing

Boon or Bane

With manufacturing costs on the rise, Aiswariya Chidambaram at Frost & Sullivan demonstrates how outsourcing has become a strategic move for pharmaceutical and biotech companies.
 
view
download pdf
Emerging Markets

Made to Measure

Vijaya Vulapalli at GBI Research investigates how emerging Asian markets are gaining on their US and European competitors by acquiring outsourcing contracts from Big Pharma.
 
view
download pdf
BioDevelopment
Biodevelopment

Body of Evidence

The cancer treatment landscape has found a powerful new approach in the form of Biological Response Modifiers. Alex Casta at Biocat explains how this technique could generate gene and cell therapies, leading to truly personalised medicine.
 
view
download pdf
Rare Disease Sustainability

The Price of Value

Tony Hall at Cudos examines the orphan drug sector and the high cost prices that rare diseases may incur. Do they put investors off?
 
view
download pdf
Collaboration in Regenerative Medicine

The Networking Game


A possible answer to the increasing cost of healthcare and diminishing resources in the pharma industry may be rectified through Regenerative Medicine, suggest Frank-Roman Lauter, Sylvie Ponchaut, Greg A Bonfiglio, Chris Mason and Boo Edgar.
 
view
download pdf
Developability

Surviving the Valley of Death

Developability looks to become a crucial area of attention in the biopharmaceutical sector. Jesús Zonda at Lonza Biologics explains how increasing drug development costs can be avoided simply by choosing suitable candidates with specific qualities.
 
view
download pdf
bullet
Drug Discovery
Drug Production

An Age of Orphans

Small markets with unmet medical needs are becoming a lucrative area, explains G Steven Burrill at Burrill & Company. Regulations and new developments are driving innovation forward as pharma makes the transition from blockbuster to niche drugs.
 
view
download pdf
RNA-Based Therapeutics

The Rise of the Nano

Anti-tumour treatments with nanoparticles in the delivery of siRNA can claim a signifi cant amount of success, but there are still a number of obstacles to tackle, as Surendra Nimesh at Health Canada illustrates.
 
view
download pdf
ADME-Tox Screening

Gene Expression Analysis

In order to regulate pricing in the drug development process, eradicating incompatible compounds at an earlier stage is needed. Determining their ADME-Tox summary could be the answer, explains Jari Rautio at Plexpress.
 
view
download pdf
Antibiotic Development

One Bug, One Drug

David Livermore and John Wain at Norwich Research Park discuss the current challenges facing antibiotic researchers as they track bacteria composition in the human body.
 
view
download pdf
bullet
BioRegional
Chinese Healthcare

One Country, Two Markets

Zhihao Yu
at Lux Research assesses the current state of China, where social class segregation is dividing the healthcare system into two distinct markets. How will the Chinese government tackle this challenge?
 
view
download pdf
BioManufacturing
Biomanufacturing

The Big Squeeze

Eric S Langer at BioPlan Associates considers the recent progression of biotechnological facilities, and presents the challenges they may face in years to come.
 
view
download pdf
bullet
CANCER FOCUS
Biologic Cancer Therapy

Therapy for the Soul

In order for cancer solutions to advance, a closer look at the design of clinical trials needs to be addressed, says David Edwards of Cancer Research UK.
 
view
download pdf
Cancer Research

Where NGS Leads

Modern genomic tools have transformed biological and clinical research, argues Dr Fang Tian at ATCC. In particular, Next Generation Sequencing appears to provide a higher calibre analysis of gene expression, which can enhance our understanding of the cancer genome.
 
view
download pdf
Haematology and Oncology

A Complex Puzzle

Daniel Mazzolenis and Swapnil Pandey at INC Research explore the complicated field of haematology and oncology, describing how the peculiarities of these biologic studies could make the difference between the success or failure of a specific project.
 
view
download pdf
bullet
INTERVIEW
Industry Interview

People Potential

Sean Russell of Premier Research discusses his career motivation and looks forward to the future of pharma.
 
view
download pdf
Industry Interview

Providing Solutions

Shayesteh Fürst-Ladani of SFL Regulatory Affairs & Scientific Communication Ltd provides advice for budding entrepreneurs and reveals her upcoming goals.
 
view
download pdf
   
spacer


Published quarterly in
January, April,
July, and October

News and Press Releases

CPhI China opens with analysis pointing to a surge in growth in 2019

Shanghai, 23rd May 2019: New analysis released ahead of CPhI & P-MEC China (#CPhIChina and #PMECChina) – co-organized by Informa Markets, CCCMHPIE, and Shanghai Sinoexpo Informa Markets – forecasts that China will continue to grow strongly through 2019/20, thanks in part to a marked improvement in its global reputation.
More info >>

White Papers

The BioPharmaSpec Approach”: Mass Spectrometry Based Host Cell Protein Identification and Quantitation

BioPharmaSpec

1. Introduction As part of the development of any biopharmaceutical product, the impurities present must be examined, minimized and where possible characterized (1). These impurities fall into two broad categories: product-related impurities (derived specifically from the drug product itself) and process-related impurities (derived from material associated with the production, processing or purification of the sample). Host cell proteins (HCPs) are process-related impurities that require specific analysis due to the multitude of naturally occurring proteins expressed in the production cell line.
More info >>

Industry Events

BioTrinity 2020

28-29 April 2020, Etc Venues, London

BioTrinity is a long-running and highly regarded two day life sciences conference that takes place in Central London from 28-29 April. BioTrinity focuses on partnering, investment and collaboration and aims to inspire growth and create opportunities for all who attend. The core delegate mix includes early-stage and emerging biotech, medtech and digital health companies, big pharma executives and life sciences investors.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement